Viking Therapeutics, Inc. (VKTX)
Nasdaq: VKTX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2014
Filings
287 filings since 2017 beside 232 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026Due nextLarge accelerated filer
10-K
Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends.
by Mar 1, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end.
by May 10, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 28 days after the quarter ended. The proxy statement was last filed Apr 1, 2026.
Filings a yearinsider forms included
37354326631035349
2026 counts to Nov 13, 2026.
Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest Apr 23, 2025.Officer or director change (8-K item 5.02): 1 time in the last 36 months, the newest May 23, 2024.SEC letters: 3 in the last 36 months, the newest Apr 21, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Sep 28, 2026
8-K items 1.01, 2.03, 9.01
Major agreement signed; New debt or obligation taken on · Current report
Sep 23, 2026
40 of 287 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.